Bill Ackman tells CNBC that his losses from betting against Herbalife have been "more than cut in half" based on the recent downturn of the company's stock.» Read More
Jason Subotky, Yacktman Funds, shares his thoughts on Coca-Cola's equity compensation plan. The problem with these plans are they are complicated and a lot of the details are not fully flushed out, says Subotky.
Anthony DiClemente, Nomura senior analyst, shares his upbeat outlook on the social media giant, as advertising dollars continue to shift towards digital media.
John Stephens, AT&T CFO, delves into Ma Bell's quarterly numbers and weighs in on the company's strategy to increase its wireless subscribers.
William Ackman, Pershing Square Capital Management, explains how his partnership with Valeant is structured. And J. Michael Pearson, Valeant chairman & CEO, discusses why he partnered with Ackman instead of pursing Allergan alone. Creating shareholder value is our job, says Pearson.
William Ackman, Pershing Square Capital Management, explains why he is helping Valeant buy Allergan.
J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, weighs in on news that Allergan has adopted a "poison pill" defense strategy. Also Pearson shares his thoughts on adding some of Allergan's notable cosmetic products like Botox and Restasis to its growing arsenal.
J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, explains why he decided to pursue Allergan and shares his R&D business model, with CNBC's Kate Kelly. This year we are launching 19 products in the United States, says Pearson.
William Ackman, Pershing Square Capital Management, explains why he decided to team up with Valeant Pharmaceuticals to make a play for Allergan.
Boeing's profit margin on the commercial side improves to 11.8 percent, reports CNBC's Phil LeBeau with a break down on Boeing's quarterly results.
Jon Moeller, Procter & Gamble CFO, breaks down the company's third quarter results of $1.04 EPS ex-items on revenues of $20.56 billion and weighs in on where the company sees global growth.
Most of these investors are looking for a dialogue to improve value, says Andrew Liveris, President, Chairman & CEO of Dow Chemical, sharing his thoughts on activist investors.
We overcame transport and weather issues in North American, says Andrew Liveris, President, Chairman & CEO of Dow Chemical, breaking down his company's first quarter results of $0.79 EPS on revenues of $14.46 billion.
It's not a dirty little secret anymore, says Heather Thomson, Yummie by Heather Thomson founder, discussing how her company is redefining the shapewear industry and carving out a piece of the market.
Investors need to separate new tech from old tech, says Christopher Wolfe, Merrill Lynch, sharing his views on whether there's a tech bubble brewing. And Mark Haefele, UBS Wealth Management, weighs in.
Chris Caso, Susquehanna Financial Group analyst, shares his outlook on Apple in the second half. Apple needs to show shareholders the next new thing, says Caso.
CNBC's Meg Tirrell digs into the friendly and hostile M&A action taking place in pharmaceuticals, including a deal between Novartis and GlaxoSmithKline, and Valeant Pharmaceuticals bid for Allergan.
Don't start your trading day without finding out what CNBC's Jim Cramer is watching ahead of the opening bell.
CNBC's Jane Wells reports on the good and bad of El Nino if it develops near South American mines, and coffee and cocoa.
McDonald's reported Q1 EPS of $1.21 on revenue of $6.7 billion. RJ Hottovy of Morningstar, still sees value in the stock.
Citi investors are in St. Louis today for the bank's annual shareholder meeting. CNBC's Kayla Tausche provides insight into the day's schedule.
Get the best of CNBC in your inbox
Joe Kernen is co-anchor of "Squawk Box," CNBC's signature morning program.
Becky Quick is co-anchor of "Squawk Box," CNBC's signature morning program. She's also a columnist for Fortune.
Andrew Ross Sorkin is a co-anchor of "Squawk Box," a financial columnist for "The New York Times" and the editor-at-large of NYT's DealBook.